Wendi Mason*, Sally McLaughlin, Sophy Dedopoulos, Erin Mahoney, Tonja Meadows, John L. Stauffer and Lisa H. Lancaster Pages 4 - 15 ( 12 )
Idiopathic pulmonary fibrosis (IPF) is a debilitating, progressive, and fatal fibrotic lung disease with a poor prognosis. Antifibrotic therapy slows but does not halt disease progression. Patient education and management needs change during disease progression. Management is complicated by comorbidities, adverse events associated with antifibrotic therapy, and difficulties with long-term oxygen therapy and pulmonary rehabilitation. Treating IPF requires coordination between physicians and nurses in community and interstitial lung disease center settings. This review provides guidance for the healthcare professional who manages the essential aspects of care in IPF from diagnosis, through disease progression, and to the end of life.
Disease management, disease progression, idiopathic pulmonary fibrosis, interstitial lung disease, nintedanib, pirfenidone.
Department of Medicine, Vanderbilt University, Nashville, Tennessee, University of California, San Francisco, San Francisco, California, Northwell Health, New Hyde Park, New York, Loyola University Medical Center, Maywood, Illinois, University of Alabama at Birmingham, Birmingham, Alabama, Genentech, Inc., South San Francisco, California, Department of Medicine, Vanderbilt University, Nashville, Tennessee